Phase III data for Obseva's uterine fibroid project linzagolix need to prove its safety, while Inventiva tests its pan-PPAR agonist lanifibranor in Nash.
Obseva awaits data that could make linzagolix third to market, while Newron looks for a starring role in Retts.
Intra-Cellular looks to shore up lumateperone, while Myovant wants to take on Abbvie on its own turf.
The decision to halt trials for the uterine fibroid product marks another setback in an area where there are few suitable solutions for patients.
A US FDA complete response letter has dealt Allergan’s hopes of finding a buyer for its women’s health unit a serious blow.
Demand for new issues remains sluggish - only eight private biotechs managed to pull off an IPO in the first quarter of 2017.